Ensign Peak Advisors
LABP

Ensign Peak Advisors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Ensign Peak Advisors’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,500
Closed -$1.82M – 2263
2021
Q3 		$1.82M Hold
12,500
– – ﹤0.01% 1180
2021
Q2 		$1.44M Hold
12,500
– – ﹤0.01% 1289
2021
Q1 		$1.2M Buy
+12,500
New +$1.63M ﹤0.01% 1353

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ensign Peak Advisors's LABP Position: Q4 2021 in Review

Ensign Peak Advisors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2021, closing a stake of 12,500 shares — an estimated $1.82M sold.

Ensign Peak Advisors first reported a position in LABP in Q1 2021 and held it in 3 quarters. The position peaked at $1.82M in Q3 2021. 40 funds tracked by Wall St. Rank hold LABP as of Q4 2021.

  • Ensign Peak Advisors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 12,500 Landos Biopharma, Inc. Common Stock shares in Q4 2021, an estimated $1.82M.
  • Ensign Peak Advisors first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Ensign Peak Advisors's Landos Biopharma, Inc. Common Stock position peaked at $1.82M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2021.

Based on Ensign Peak Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.